These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21242335)

  • 1. Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug.
    Tuma RS
    J Natl Cancer Inst; 2011 Feb; 103(3):170-1, 177. PubMed ID: 21242335
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug discovery: How melanomas bypass new therapy.
    Solit D; Sawyers CL
    Nature; 2010 Dec; 468(7326):902-3. PubMed ID: 21164474
    [No Abstract]   [Full Text] [Related]  

  • 3. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to BRAF inhibition in melanomas.
    Solit DB; Rosen N
    N Engl J Med; 2011 Feb; 364(8):772-4. PubMed ID: 21345109
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
    Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
    Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mutated BRAF in melanoma.
    Kim T; Kim J; Lee MG
    N Engl J Med; 2010 Dec; 363(23):2261; author reply 2261-2. PubMed ID: 21121840
    [No Abstract]   [Full Text] [Related]  

  • 8. PLX4032 and melanoma: resistance, expectations and uncertainty.
    Roukos DH
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):325-8. PubMed ID: 21417847
    [No Abstract]   [Full Text] [Related]  

  • 9. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
    Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
    Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors.
    Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P
    Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards new therapeutic approaches for malignant melanoma.
    Pacheco I; Buzea C; Tron V
    Expert Rev Mol Med; 2011 Nov; 13():e33. PubMed ID: 22044938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
    Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F
    Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic RAF: a brief history of time.
    Solit D; Rosen N
    Pigment Cell Melanoma Res; 2010 Dec; 23(6):760-2. PubMed ID: 20973931
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
    Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
    Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.
    Rajakulendran T; Adam DN
    Int J Dermatol; 2014 Dec; 53(12):1428-33. PubMed ID: 25311997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
    Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
    Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.